Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B405b0c9e43b1286f7c8b5f24c01c22f9> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B405b0c9e43b1286f7c8b5f24c01c22f9 NCIT_P378 "NCI" @default.
- B405b0c9e43b1286f7c8b5f24c01c22f9 type Axiom @default.
- B405b0c9e43b1286f7c8b5f24c01c22f9 annotatedProperty IAO_0000115 @default.
- B405b0c9e43b1286f7c8b5f24c01c22f9 annotatedSource NCIT_C114984 @default.
- B405b0c9e43b1286f7c8b5f24c01c22f9 annotatedTarget "An orally bioavailable inhibitor of the tyrosine kinases tropomyosin receptor kinases (Trk) A, B and C, C-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK), with potential antineoplastic activity. Upon administration, entrectinib binds to and inhibits TrkA, TrkB, TrkC, ROS1 and ALK. Inhibition of these kinases may result in a disruption of TrkA-, TrkB-, TrkC-, ROS1-, and ALK-mediated signaling. This leads to an induction of apoptosis and an inhibition of tumor cell proliferation in tumor cells that express these kinases. TrkA, TrkB, TrkC, ROS1 and ALK are overexpressed in a variety of cancer cell types." @default.